Table 3 Griseofulvin levels in plasma and RBCs.

From: Griseofulvin impairs intraerythrocytic growth of Plasmodium falciparum through ferrochelatase inhibition but lacks activity in an experimental human infection study

Study and cohort

Peak griseofulvin levels (μg/L) a (range) b

Coefficient of variation (%)

p value c

Plasma

  

0.013

ex vivo study 1,000 mg dose Plasma

1,830 (1,776, 1,884)

3

 

ex vivo study 2,000 mg dose Plasma

1,234

NA

 

IBSM study Cohort 1 Plasma

1,378 (1,201, 1,588)

12.1

 

IBSM study Cohort 2 Plasma

1,079 (821, 1,337)

33.8

 

RBCs

  

0.21

ex vivo study 1,000 mg dose RBC

110 (59, 143)

40.9

 

ex vivo study 2,000 mg dose RBC

63

NA

 

IBSM study Cohort 1 RBC

149 (123, 184)

20.2

 

IBSM study Cohort 2 RBC

86 (55, 117)

51.0

 
  1. aPeak griseofulvin levels are expressed as average.
  2. bRange values for the 2,000 mg dose of the ex vivo study are not provided because only one subject was dosed.
  3. cANOVA was used to compare peak griseofulvin levels values between cohorts (p value was significant if p < 0.05). The 2,000 mg dose of the ex vivo study was not included in this analysis since this group had only one subject and therefore was not appropriate to be included in the analysis. NA, not analyzed.
Back to article page